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costs were also modeled using linear regression. In this
model the “Grier-effect” was estimated by using a dummy
variable. RESULTS: For all months (November 2000–
July 2001) projected PMPM cost of antibiotic therapy
was lower than actual PMPM cost of antibiotic therapy.
The r-squared for the model was 0.96. The 9-month
average for projected PMPM antibiotic costs was $2.52
and actual PMPM antibiotic costs were $3.51, for an
average differential of nearly $1.00. The extrapolated
cost differential over the forecasted 9-month period was
$12.5 million. This translates into $16.7 million in addi-
tional annual costs for antibiotic therapy due to the
“Grier-effect”. Regression analysis of the effects of Grier
indicated the GCD increased expenditures for antibiotics
by 30% (p < 0.0001). According to regression modeling,
a 30% increase in expenditures due to Grier increased
costs of antibiotic therapy by $18.3 million. CONCLU-
SIONS: The GDC signiﬁcantly increased antibiotic
expenditures, resulting in an additional ~$17–18 million
in annual costs. Additional research is necessary to assess
whether this increase improved quality.
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OBJECTIVE: Community Acquired Pneumonia (CAP) is
a major cause of mortality and healthcare resource use
worldwide. Proper management of less severe outpatient
CAP has demonstrated resource savings without adverse
patient outcomes. Although treatment guidelines recom-
mend the use of certain pharmacological agents such as
macrolides, ﬂuoroquinolines or doxycycline for outpa-
tient CAP, limited data are available on actual usage. We
aim to describe current antibiotic prescribing patterns
using a large prescription database. METHODS: The
study population comprised IMS MediPlus-UK. Adult
CAP outpatients (ICD-10: J13–J15) diagnosed during
January 1, 1997 through December 31, 2001 and treated
with antibiotics were included. Patients were followed
through the initial duration of therapy and an additional
4-week period to capture the original therapy and 
added antibiotic use. Those with HIV/AIDS were
excluded. Antibiotics were categorized as “penicillins”,
“cephalosporins”, “macrolides”, “tetracyclines”, “quino-
lones”, and “other” (including multisubstance and
trimethoprim). RESULTS: Among 739 episodes identi-
ﬁed, most were initially treated by penicillin group
(including amoxicillin, ampicillin, penicillin, 41%), and
macrolides (erythromycin, azithromycin, clarithromyc,
28%). Cephalosporins, tetracyclines, and quinolones
were used less often, 10%, 4% and 5%, respectively. The
median prescribed length of therapy was 7 days, except
tetracyclines (6). The means (days)(standard deviation)
were: 6.9(2.8)for penicillins, 7.4(1.9)for cephalosporins,
9.5(17.2) for macrolides, 6.3(2.5) for tetracyclines,
6.4(1.5) for quinolones, and 6.7(1.5) for other. The per-
centage of patients received a second antibiotic during
study period ranged from 15% to 23%, with the second
round mostly in the same category as the initial antibi-
otic. CONCLUSIONS: Duration of therapy for CAP out-
patients remains relatively long in this UK population. 
A substantial proportion of patients received additional
therapy during the episode of care. Long therapy dura-
tion has been associated with patient nonadherence,
and/or treatment failure. Effective therapy options with
shorter length of therapy are needed to improve CAP out-
patient management and patient outcomes.
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OBJECTIVE: In February 2001, the Ontario Drug Beneﬁt
(ODB) Formulary was changed so that most ﬂuoro-
quinolone (FQ) antibiotics would be subject to Limited
Use (LU) restrictions. Only norﬂoxacin remained as
General Beneﬁt (GB). This study analyzed the impact 
of the LU policy on ODB antibiotic volume and expen-
ditures. METHODS: We analysed monthly ODB data on
prescribing volumes and expenditures of 29 types of
antibiotics over the period (January 1999 to November
2001). Ordinary least squares (OLS) regression with a
robust estimator of the standard errors was used to esti-
mate the effect of LU on the pre-policy trend in antibi-
otic use and expenditures. Estimates from these models
were used to predict the cumulative impact of LU on out-
comes in the 10 month post-LU policy period (February
to November 2001). RESULTS: Of the 29 types of antibi-
otics included in this analysis (with total ODB prescrip-
tions and expenditures of 2.3 million and CDN$55
million in 2000), changes for ciproﬂoxacin and nor-
ﬂoxacin were the greatest in magnitude. We observed a
shift in prescriptions and expenditures from LU FQs 
(-167,764, p < 0.00; -$8,963,635, p < 0.00, respectively)
to GB FQs (45,126, p < 0.00; $2,069,956, p < 0.00).
However, while FQ prescriptions and expenditures
decreased signiﬁcantly (-118,020, p < 0.00; -$6,662,708,
p < 0.00), we found no signiﬁcant change in either total
number of antibiotics prescribed or total antibiotic expen-
ditures after LU. Also, prescriptions for trimethoprim sul-
famethoxazole (TMP/SMX) increased signiﬁcantly.
CONCLUSIONS: Although no direct cause and effect
can be shown with these observational data, the results
suggest that the change in reimbursement policy to
restrict prescribing of FQs did not signiﬁcantly affect
overall ODB antibiotic prescriptions and expenditures.
Although use of and expenditures on restricted FQs were
reduced signiﬁcantly, there was an offsetting increase in
